Participated · Series A · Jun 2026

Founded in 2021, RQ Bio is developing long-acting monoclonal antibody therapeutics aimed at providing immediate and durable protection against seasonal influenza. Its lead programme, RQB01, is in IND-enabling studies and is designed to deliver broad strain coverage and extended duration of action via a differentiated dual mechanism targeting conserved epitopes. The company aims to provide season-long protection with a single administration, particularly for immunocompromised and high-risk patients. RQ Bio has an experienced team with prior success in developing long-acting antiviral antibodies and is backed by a syndicate of life sciences investors. The recent $115 million Series A will fund clinical development of RQB01 and further advance the company's antibody discovery platform. Leadership was strengthened with the appointment of Christian S. Schade as Executive Chairman.

Participated · Series A · May 2026

Cytospire Therapeutics develops differentiated multispecific engager antibodies that bind and activate both tissue/tumour and blood-resident gamma delta T cells to direct innate and adaptive effector immune responses. Its core technology aims to enable safer and more efficacious targeting of validated antigens that are intractable to CD3 T cell engagers due to toxicity. The company's lead programme, CYT X300, is in IND-enabling preclinical studies while the firm is advancing GMP manufacturing for the asset. Cytospire plans to use its newly raised Series A proceeds to progress this pipeline work. The company is led by CEO Natalie Mount. Recent corporate developments include strengthening the board with appointments from participating investors following the financing.

Participated · Series B · Jan 2026

Founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu, Exciva focuses on therapies for neuropsychiatric symptoms in Alzheimer’s disease dementia and related brain disorders. Its lead candidate, Deraphan, combines two CNS-active compounds designed to reduce agitation in Alzheimer’s patients. The company is currently preparing and financing a Phase 2 clinical study to evaluate Deraphan’s therapeutic potential. Exciva leverages proprietary discovery capabilities to identify synergistic compound combinations addressing unmet neuropsychiatric needs. The latest capital infusion strengthens its balance sheet and extends runway through critical mid-stage clinical development. While the company has not disclosed revenue or patient enrollment numbers, the new financing underscores investor confidence in its scientific approach and market opportunity. The refreshed board now includes representatives from key new and existing investors, ensuring broad strategic guidance as the program advances.

Led · Series A · Mar 2025

Tribune Therapeutics is advancing novel medicines to treat fibrosis regardless of cause, tissue, or diagnosis by targeting central, tissue‑agnostic drivers of scar formation in the CCN protein family. Its lead program, TRX‑44, is a CCN5 mimic designed to prevent scar formation by blocking the pro‑fibrotic effects of CTGF/CCN2 and WISP1/CCN4 across multiple cell types. The company’s approach aims to be broader than blocking individual CCN proteins or upstream activators like TGF‑beta, with the potential to avoid toxicities that have hindered less targeted strategies. Tribune is advancing multiple programs targeting CCN biology and plans to use new funding to prepare TRX‑44 to enter clinical trials for fibrotic indications including idiopathic pulmonary fibrosis (IPF). Tribune, based in Stockholm and Oslo, raised a total of €37 million in seed and Series A financings to support these programs. The financing and accompanying board additions are intended to advance the company’s preclinical programs toward the clinic. Tribune Therapeutics is a preclinical biopharmaceutical company founded in 2020 in Oslo developing medicines that exploit a novel pan-antifibrotic mechanism. The company in-licensed a breakthrough asset from Inven2 based on research from Håvard Attramadal’s lab. Its lead program targets fibrotic diseases affecting the kidney, lung and liver, and Tribune is building a pipeline across multiple fibrotic indications. Tribune was co-created and funded by HealthCap and Novo Seeds (the early-stage arm of Novo Holdings) and launched from stealth with seed financing. Leadership appointments associated with the launch include Executive Chairman Jonas Hansson, incoming CEO Georg Vo Beiske, and CSO Ole Jørgen Kaasbøll. The company is preclinical and no operating metrics or revenue figures are disclosed in the articles.

Led · Series A · Mar 2025

Hillstar Bio develops next-generation precision immunology therapies that selectively deplete pathogenic immune cells while preserving healthy cells. Its lead program targets TRBV9+ T cells and is being advanced toward a clinical proof-of-concept study in axial spondyloarthritis and other HLA-B27-associated conditions. The company plans to initiate clinical trials for the TRBV9 program in 2026. Hillstar leverages tailored discovery techniques, validated technologies, and disease-specific biomarkers to identify patient populations and mitigate development risk. The company is backed by an investor syndicate and says it is fully funded through early clinical studies following the recent financing. Hillstar highlights a leadership team with deep expertise in antibody engineering, immunology, and clinical development.